Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Microbiology

Vol 9 No 2 (2024): December

Isoxazolidine Derivatives Exhibit Selective Antitumor Activity Against Breast Cancer Cells
Turunan Isoxazolidine Menunjukkan Aktivitas Antitumor Selektif Terhadap Sel Kanker Payudara



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.8148
Published
October 17, 2023

Abstract

Breast cancer, a leading cause of cancer-related mortality in women, necessitates effective therapeutic interventions. Heterocyclic compounds, prevalent in FDA-approved pharmaceuticals, play a pivotal role in drug development. This study focuses on isoxazolidine derivatives, a subgroup of nitrogen and oxygen-containing heterocycles, known for their potential in antitumor applications. A series of novel isoxazolidine compounds were synthesized and evaluated for their anticancer efficacy using MTT assays against MCF-7 and HdFn cell lines, alongside normal cells. Structural elucidation employed FT-IR, 13C-NMR, 1H-NMR, and E-I mass spectroscopy. Results revealed compound (IZ3) with an IC50 value of 32.49 µg/ml, demonstrating notable antitumor activity in MCF-7 cells compared to HdFn. Notably, compounds (IZ1 and IZ2) exhibited IC50 values of 64 µg/ml and 128 µg/ml, respectively. These findings underscore the potential of isoxazolidine derivatives as promising candidates for targeted breast cancer therapies, warranting further investigation in preclinical models and clinical trials.

Highlight:

  • Novel Isoxazolidine Compounds: Synthesized and Evaluated
  • Selective Antitumor Activity: Demonstrated in MCF-7 Breast Cancer Cells
  • Promising Therapeutic Candidates: Isoxazolidine Derivatives for Targeted Breast Cancer Therapy

Keyword: Breast cancer, Isoxazolidine Derivatives, Antitumor Activity, Heterocyclic Compounds, Drug Development

References

  1. A. N. Giaquinto, H. Sung, K. D. Miller, J. L. Kramer, L. A. Newman, A. Minihan, et al., "Breast cancer statistics, 2022," CA Cancer J Clin, vol. 72, no. 6, pp. 524–541, Nov. 2022.
  2. M. G. Salem, D. M. A. El-Maaty, Y. I. M. El-Deen, B. H. Elesawy, A. E. Askary, A. Saleh, et al., "Novel 1,3-thiazole analogues with potent activity against breast cancer: A design, synthesis, in vitro, and in silico study," Molecules, vol. 27, no. 15, p. 4898, Jul. 2022. [Online]. Available: https://www.mdpi.com/1420-3049/27/15/4898
  3. F. Alminderej, S. Ghannay, M. Elsamani, F. Alhawday, A. Albadri, S. Elbehairi, et al., "In vitro and in silico evaluation of antiproliferative activity of new isoxazolidine derivatives targeting EGFR: Design, synthesis, cell cycle analysis, and apoptotic inducers," Pharmaceuticals, vol. 16, no. 7, p. 1025, Jul. 2023. [Online]. Available: https://www.mdpi.com/1424-8247/16/7/1025
  4. G. Ram Gopal KVRSS, A. V. Lakshmi, and C. R. Kumar, "Anticancer herbs in Ayurveda: A review," Int J Res Ayurveda Pharm, vol. 4, no. 2, pp. 284–287, Apr. 2013.
  5. G. M. Muhabil, "Study the correlation between serum levels of PD-1/PD-L1, IFN-γ, and tumor marker CA 15-3 with demographic and clinical pathological characteristics of breast cancer patients," 2014.
  6. R. Hesketh, "Introduction to cancer biology," Cambridge University Press, 2012.
  7. N. A. Lafta, "Evaluation of α-amylase levels, some biochemical parameters and inhibitors in sera of breast cancer patients," Feb. 2023.
  8. Y. Feng, M. Spezia, S. Huang, C. Yuan, Z. Zeng, L. Zhang, et al., "Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis," Genes Dis, vol. 5, no. 2, pp. 77–106, Jun. 2018.
  9. I. A. Siddiqui, V. Sanna, N. Ahmad, M. Sechi, and H. Mukhtar, "Resveratrol nanoformulation for cancer prevention and therapy," Ann N Y Acad Sci, vol. 1348, no. 1, pp. 20–31, Aug. 2015.
  10. P. Martins, J. Jesus, S. Santos, L. Raposo, C. Roma-Rodrigues, P. Baptista, et al., "Heterocyclic anticancer compounds: Recent advances and the paradigm shift towards the use of nanomedicine’s tool box," Molecules, vol. 20, no. 9, pp. 16852–16891, Sep. 2015. [Online]. Available: http://www.mdpi.com/1420-3049/20/9/16852
  11. A. Gomtsyan, "Heterocycles in drugs and drug discovery," Chem Heterocycl Compd, vol. 48, no. 1, pp. 7–10, Apr. 2012. [Online]. Available: http://link.springer.com/10.1007/s10593-012-0960-z
  12. T. Qadir, A. Amin, P. K. Sharma, I. Jeelani, and H. Abe, "A review on medicinally important heterocyclic compounds," Open Med Chem J, vol. 16, no. 1, Apr. 2022. [Online]. Available: https://openmedicinalchemistryjournal.com/VOLUME/16/ELOCATOR/e187410452202280/
  13. T. Eicher, S. Hauptmann, and A. Speicher, "The chemistry of heterocycles," Wiley, 2003. [Online]. Available: https://onlinelibrary.wiley.com/doi/book/10.1002/352760183X
  14. H. Broughton and I. A. Watson, "Selection of heterocycles for drug design," J Mol Graph Model, vol. 23, no. 1, pp. 51–58, Sep. 2004. [Online]. Available: https://linkinghub.elsevier.com/retrieve/pii/S1093326304000397
  15. M. S. Salem, S. I. Sakr, W. M. El-Senousy, and H. M. F. Madkour, "Synthesis, antibacterial, and antiviral evaluation of new heterocycles containing the pyridine moiety," Arch Pharm (Weinheim), vol. 346, no. 10, pp. 766–773, Oct. 2013. [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/ardp.201300183
  16. X. Cao, Z. Sun, Y. Cao, R. Wang, T. Cai, W. Chu, et al., "Design, synthesis, and structure–activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility," J Med Chem, vol. 57, no. 9, pp. 3687–3706, May 2014. [Online]. Available: https://pubs.acs.org/doi/10.1021/jm4016284
  17. L. Maiuolo and A. De Nino, "Synthesis of isoxazolidines by 1,3-dipolar cycloaddition: Recent advances," Targets Heterocycl Syst, vol. 19, pp. 299–345, 2015.
  18. M. Azab, M. Youssef, and E. El-Bordany, "Synthesis and antibacterial evaluation of novel heterocyclic compounds containing a sulfonamido moiety," Molecules, vol. 18, no. 1, pp. 832–844, Jan. 2013. [Online]. Available: http://www.mdpi.com/1420-3049/18/1/832
  19. Y. Chen, K. Yu, N. Y. Tan, R. H. Qiu, W. Liu, N. L. Luo, et al., "Synthesis, characterization and anti-proliferative activity of heterocyclic hypervalent organoantimony compounds," Eur J Med Chem, vol. 79, pp. 391–398, May 2014. [Online]. Available: https://linkinghub.elsevier.com/retrieve/pii/S0223523414003456
  20. E. R. El-Sawy, M. S. Ebaid, H. M. Abo-Salem, A. G. Al-Sehemi, and A. H. Mandour, "Synthesis, anti-inflammatory, analgesic and anticonvulsant activities of some new 4,6-dimethoxy-5-(heterocycles)benzofuran starting from naturally occurring visnagin," Arab J Chem, vol. 7, no. 6, pp. 914–923, Dec. 2014. [Online]. Available: https://linkinghub.elsevier.com/retrieve/pii/S1878535213000129
  21. E. R. El-Sawy, A. H. Mandour, S. M. El-Hallouty, K. H. Shaker, and H. M. Abo-Salem, "Synthesis, antimicrobial and anticancer activities of some new N-methylsulphonyl and N-benzenesulphonyl-3-indolyl heterocycles," Arab J Chem, vol. 6, no. 1, pp. 67–78, Jan. 2013. [Online]. Available: https://linkinghub.elsevier.com/retrieve/pii/S1878535212000718
  22. J. Alvarez-Builla and J. Barluenga, "Heterocyclic compounds: An introduction," ChemInform, vol. 43, no. 1, Jan. 2012. [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/chin.201201253
  23. P. Yuan, R. Liu, H. Zhu, Z. Liao, J. Xiang, and A. Wu, "An I2–DMSO catalytic manifold enabled aromatization for C-ring editing of podophyllotoxone," Org Biomol Chem, 2023.
  24. K. C. Nicolaou and E. J. S. Classics in Total Synthesis: Targets, Strategies, Methods, 1996, 821 p.
  25. L. D. Bastin, M. Nigam, S. Martinus, J. E. Maloney, L. L. Benyack, and B. Gainer, "Of substituted N-phenylmaleimides and use in a Diels–Alder reaction: A green multi-step synthesis for an undergraduate organic chemistry laboratory," Synth Approaches to Nonaromatic Nitrogen Heterocycles, 2 Vol Set, pp. 127–135, 2019.
  26. K. C. Nicolaou and S. A. (Scott A.) Snyder, "Classics in total synthesis. Vol. 2, More targets, strategies, methods," 2003, 639 p.
  27. H. H. Salman, M. A. M. Ali, and E. T. Ali, "Synthesis and screening of anticancer potentials of some new terephthaldehyde-derived nitrone compounds," Trop J Pharm Res, vol. 19, no. 2, pp. 341–349, 2020.
  28. M. Yusuf, Shehneela, and B. Singh, "Synthesis and antimicrobial evaluation of new pyrrolo-isoxazolidine derivatives," Asian J Chem, vol. 31, no. 1, pp. 220–228, 2019.
  29. H. H. Salman and N. N. Majeed, "Synthesis, characterization and study of biological activity of some new nitrone and isoxazolidine compounds," J Basrah Res, vol. 39, no. 2, pp. 99–111, 2013.
  30. G. G. Wubbels and R. L. Letsinger, "Photoreactions of nitrobenzene and monosubstituted nitrobenzenes with hydrochloric acid. Evidence concerning the reaction mechanism," J Am Chem Soc, vol. 96, no. 21, pp. 6698–6706, Oct. 1974.
  31. M. Martina, "Synthesis and reactivity of N-substituted isatins and related compounds," 2023.
  32. L. S. Doyle and S. B. NH-Isoxazolidines, "Isoxazolidines as Organocatalysts," Oct. 2009.
  33. A. Noori, M. Qaddo, and A. A. Abed, "Heterocyclic synthesis of some new isoxazolidine derivatives via 1,3-dipolar cycloaddition of nitrones to styrene ىلإ تانورتينمل ةيقمحلا ةفاضلإا لعافت ربع ةديدجلا نيديلوزادكوزيلأا تاقتذم ضعب ريضحت نيرياتدلا," vol. 63, no. 10, pp. 4175–4184, 2022.
  34. J. H. Mohammed and N. A. M. Salih, "Synthesis and characterization of some new nitrone derivatives and screening their biological activities," 2022, pp. 268–273.
  35. M. A. Chiacchio, L. Legnani, and U. Chiacchio, "Recent advances in the synthesis of isoxazolidines," Synth Approaches to Nonaromatic Nitrogen Heterocycles, 2 Vol Set, pp. 161–177, 2020.
  36. A. Ghabi, J. Brahmi, F. Alminderej, S. Messaoudi, A. Kadri, K. Aouadi, et al., "Multifunctional isoxazolidine derivatives as α-amylase and α-glucosidase inhibitors," 2020.
  37. H. Mosbah, H. Chahdoura, A. Mannai, and M. Snoussi, "Biological activities evaluation of enantiopure isoxazolidine derivatives: In vitro, in vivo and in silico studies," 2018.
  38. F. Heaney, O. Rooney, D. Cunningham, and P. McArdle, "Simultaneous double 1,3-dipolar cycloaddition reactions involving bisnitrones or bisdipolarophiles. 1H NMR investigation of the conformational preferences of N-methyl- and N-phenyl-isoxazolidines," J Chem Soc Perkin Trans 2, no. 3, pp. 373–378, 2001.
  39. L. Maiuolo and A. De Nino, "Synthesis of isoxazolidines by 1,3-dipolar cycloaddition: Recent advances," Targets Heterocycl Syst, vol. 19, pp. 299–345, 2015.
  40. S. Ghannay, S. Bakari, M. Msaddek, S. Vidal, A. Kadri, K. Aouadi, et al., "Design, synthesis, molecular properties and in vitro antioxidant and antibacterial potential of novel enantiopure isoxazolidine derivatives," Arab J Chem, vol. 13, no. 1, pp. 2121–2131, Jan. 2020.
  41. M. M. Alawad, M. F. Mahdi, and A. M. R. Raauf, "Molecular docking study, and in vitro evaluation of antitumor activity of some new isoxazoline and pyrazoline derivatives of nabumetone against breast cancer cell line (MCF-7)," Al Mustansiriyah J Pharm Sci, vol. 22, no. 3, pp. 24–34, 2022.
  42. S. Ramazi, M. Salimian, A. Allahverdi, S. Kianamiri, and P. Abdolmaleki, "Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line," Sci Rep, vol. 13, no. 1, pp. 1–13, 2023.
  43. A. Capes-Davis, "Freshney’s culture of animal cells: A manual of basic technique and specialized applications, 8th edition," 832 p.
  44. Y. S. Mostafa, S. A. Alamri, M. Y. Alfaifi, S. A. Alrumman, S. E. I. Elbehairi, T. H. Taha, et al., "L-Glutaminase synthesis by marine Halomonas meridiana isolated from the Red Sea and its efficiency against colorectal cancer cell lines," Molecules, vol. 26, no. 7, p. 1963, Mar. 2021.
  45. Y. Fan, Y. Lu, X. Chen, B. Tekwani, X. C. Li, and Y. Shen, "Anti-leishmanial and cytotoxic activities of a series of maleimides: Synthesis, biological evaluation and structure-activity relationship," Molecules, vol. 23, no. 11, p. 2878, Nov. 2018.

Downloads

Download data is not yet available.